Appeal No. 2006-0760
Application No. 10/312,417
claim 13 as representative of the first grouping. For the second grouping,
the claims stand or fall together because Appellant has not provided separate
arguments for patentability of any of the claims. We select claim 20 as
representative claim of the second grouping. 37 C.F.R. § 41.37(c)(1)(vii).
13. A dermal therapeutic system comprising as an active
pharmaceutical ingredient for the treatment of symptoms associated
with irritation from degenerative joint disorders and for the treatment
of postoperative and menstrual pain at least one COX-2 inhibitor,
characterized in that the COX-2 inhibitor is a 3-aryl-4-(4-
methylsulfonylphenyl)-2(H5) furanone or a 4-[5-aryl-3-
(trifluoromethylpyrazol- 1-yl]benzenesulfonamide.
20. A dermal therapeutic system for the delivery of a medical
substance to the skin, which consists of:
a) a support layer, which is impermeable to the medical substance;
b) a reservoir or matrix layer that contains the medical substance
wherein said medical substances consists of:
1. at least one COX-2 inhibitor wherein said COX-2 inhibitor is
selected from the group consisting of 3-aryl-4-(4-
methylsulfonylphenyl)-2(H5) furanones and 4-[5-aryl-3-
(trifluoromethylpyrazol-1-yl]benzenesulfonamides; and
2. optionally, at least one compounds selected from the group
consisting of a plasticizers, tackifiers, stabilizers, fillers, carrier
and permeation enhancer(s);
wherein, said permeation enhancer(s), when present, is (are) a
compound selected from the group consisting of fatty alcohols, fatty
acids, polyoxyethylene fatty alcohols ethers, sorbitan monolaurate,
long-chain fatty acids with methyl, ethyl or isopropyl alcohols, esters
of fatty alcohols with acetic or lactic acid, and oleic acid
diethanolamine, and
wherein, when a reservoir layer is present, said reservoir layer
optionally contains a high viscosity liquid, a semisolid matrix, a
thixotropic matrix, and/or a gel former;
c) optionally, a control membrane;
2
Page: Previous 1 2 3 4 5 6 7 8 9 10 11 12 Next
Last modified: September 9, 2013